Clinical trial
An Adaptative Randomized Phase II Study on the Timing of FOLFOX for Patients With Operable Stage III Rectal Cancer
NCT01274962 is registered in ClinicalTrials.gov with Sir Mortimer B. Davis - Jewish General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Adaptative Randomized Phase II Study on the Timing of FOLFOX for Patients With Operable Stage III Rectal Cancer
- Lead sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2009
- Completion date
- December 31, 2022
- Enrollment
- 180 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
operable t2-3n+m0 rectal cancer (stage iii)